1997
The transcriptional activator Sp1, a novel autoantigen
Spain T, Sun R, Gradzka M, Lin S, Craft J, Miller G. The transcriptional activator Sp1, a novel autoantigen. Arthritis & Rheumatism 1997, 40: 1085-1095. PMID: 9182919, DOI: 10.1002/art.1780400613.Peer-Reviewed Original ResearchConceptsTranscriptional activator Sp1Novel autoantigenComplex of DNAGC-rich sequencesActivator Sp1Undifferentiated connective tissue diseaseSp1 proteinTranscription activatorConnective tissue diseaseExtractable nuclear antigensEpstein-Barr virusSp1Nuclear extractsCellular DNAMalar rashAntinuclear antibodiesClinical characteristicsProteinDNARaynaud's phenomenonTissue diseaseAutoantigenic proteinsAutoimmune seraElectrophoretic mobilityAutoantigens
1972
Prospective study of Epstein-Barr virusinfections in acute lymphoblastic leukemia of childhood
Miller G, Shope T, Heston L, O'Brien R, Schwartz A, Pearson H. Prospective study of Epstein-Barr virusinfections in acute lymphoblastic leukemia of childhood. The Journal Of Pediatrics 1972, 80: 932-937. PMID: 4337277, DOI: 10.1016/s0022-3476(72)80004-0.Peer-Reviewed Original ResearchConceptsEBV antibodiesProspective studyLymphoblastoid cell linesAcutelymphoblastic leukemiaEpstein-Barr virus infectionAntibody-positive childrenAntibody-negative patientsEBV antibody titersAcute lymphoblastic leukemiaCourse of leukemiaCell linesEBV infectionInfectious mononucleosisUntreated patientsMaternal antibodiesCongenital leukemiaSerologic evidenceAntibody titersLymphoblastic leukemiaVirus infectionPatientsLeukemiaProgressive declineEBVUndetectable levels